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Abstract 
Spondyloarthritis (SpA) is a term referring to a group of inflammatory diseases that includes 
psoriatic arthritis, axial spondyloarthritis and nonradiographic axial spondyloarthritis, 
reactive arthritis, enteropathic arthritis and undifferentiated SpA. The disease subtypes share 
clinical and immunological features including the following: joint inflammation (peripheral 
and axial skeleton); skin, gut and eye manifestations; and the absence of diagnostic 
autoantibodies (seronegative). The diseases also share genetic factors. The aetiology of SpA 
is still the subject of research by many groups worldwide. Evidence from genetic, 
experimental and clinical studies has accumulated to indicate a clear role for the interleukin-
17 (IL-17) pathway in the pathogenesis of SpA. The IL-17 family consists of IL-17A, IL-
17B, IL-17C, IL-17D, IL-17E and IL-17F, of which IL-17A is the most well-studied. IL-17A 
is a proinflammatory cytokine that also has capacity to promote angiogenesis and 
osteoclastogenesis. Of the six family members, IL-17A has the strongest homology with IL-
17F. In this Review, we discuss how IL-17A and IL-17F and their cellular sources might 
contribute to the immunopathology of SpA. 
 
Introduction 
The IL-17 family consists of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F, of which 
IL-17A, commonly referred to as IL-17, is the best characterised member. IL-17A was 
identified in 1993 when it was referred to as cytotoxic T lymphocyte antigen-8 (CTLA-8) 1 
(Figure 1 and Box 1). As we discuss later in this Review, IL-17A was initially described as a 
product of CD4+ T cells (Box 2) but is now known to be produced by CD8+ T cells,  T 
cells, natural killer T (NKT) cells, mucosal-associated invariant T (MAIT) cells and a range 
of other immune cells. The expression of IL-17A is regulated by inflammatory cytokines. 
Specifically, the relationship between IL-23 and IL-17 has led to the concept of the IL-23/IL-
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17 axis as a pivotal pathway contributing to host protection and inflammation (Figure 1, Box 
2) 2,3. 
 
IL-17A has been implicated in the immunopathology of several inflammatory diseases, 
including inflammatory arthritis (reviewed elsewhere 3,4), and its effector function has been 
extensively studied. IL-17A signalling in IL-17 receptor-bearing target cells (Box 3) 
including fibroblasts, epithelial cells and synoviocytes results in the transcription of 
proinflammatory genes, leading to the secretion of a range of proinflammatory cytokines 
(including IL-6, TNF and IL-1) 5, T cell and myeloid-cell-attracting chemokines (CC-
chemokine ligand 20 (CCL20), CCL2 and CCL7) 6,7 and neutrophilic granulocyte-attracting 
chemokines (CXC-chemokine ligand 1 (CXCL1), CXCL2, CXCL5 and CXCL8) 5,8. 
Additionally, IL-17A enhances the production and secretion of granulocyte colony 
stimulating factor (G-CSF) and granulocyte-macrophage (GM)-CSF in stromal cells, 
macrophages and T cells, thereby enhancing granulopoiesis 9. IL-17A also regulates 
production of antimicrobial peptides (defensins and S100 proteins) by IL-17 receptor-bearing 
target cells 10.  
 
Although IL-17A has an important role in inflammation and host protection against specific 
pathogens, excessive activation of this pathway can contribute to autoimmunity or chronic 
inflammatory disease. In the context of inflammatory arthritis, IL-17A can induce the 
production of matrix metalloproteinases (MMPs) (matrix metalloproteinase 1 (MMP1), 
MMP9 and MMP13) from target cells, thereby driving the degradation of extracellular matrix 
within the joint 11,12. Furthermore, IL-17A can upregulate receptor activator of nuclear factor-
kB (NF-kB) ligand (RANKL; also known as TNFSF11) expression by osteoblasts, which can 
subsequently lead to osteoclast activation and bone destruction 13. IL-17A also promotes 
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angiogenesis, thus increasing blood flow and facilitating the influx of inflammatory cells into 
the inflamed joint 14,15.  
 
Several reports have shown that IL-17F functions in a similar manner to IL-17A, albeit with 
less potency; the literature describes a hierarchy in inflammatory potential with IL-17A 
homodimers eliciting the strongest inflammatory response, followed by IL-17AF 
heterodimers, and then IL-17F homodimers 16. IL-17F has been shown to upregulate 
proinflammatory mediators including IL-6, CXCL1, CXCL8, GM-CSF, CCL2, CCL7 and 
MMP13 in fibroblasts and epithelial cells 17,18. Furthermore, IL-17F has been linked to 
neutrophilia in the context of severe asthma19.  
 
These experimental data demonstrate the potent proinflammatory, osteoclastogenic and 
angiogenic capacity of IL-17A and/or IL-17F and suggest that these cytokines are critical 
drivers of inflammation. In this Review, we consider evidence from genetic studies, 
experimental models, in vitro experiments and clinical studies that implicate the IL-23/IL-17 
axis and the cells that produce IL-17, in particular CD8+ T cells, in the immunopathogenesis 
of spondyloarthritis (SpA).  
 
The evolving concept of spondyloarthritis  
In 1859, Garrod distinguished immune-mediated inflammatory arthritis from gout and 
tuberculous arthritis 20,21. Clinical pattern recognition remained paramount in identifying 
arthritis subtypes until the discovery of rheumatoid factor 22 provided a pathological basis for 
the division of seropositive and seronegative arthritis groups. Ankylosing spondylitis (AS), 
which primarily affects the spine, was recognised as a specific clinical entity in 1973, with 
reports of a strong relationship with HLA-B27 genotype confirming a different genetic basis 
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to rheumatoid arthritis (RA) 23,24. Peripheral seronegative arthritis was less well defined until 
the recognition of overlapping clinical features occurring in people with the skin condition 
psoriasis; Moll and Wright thus coined the term psoriatic arthritis (PsA) in 1963 25. The 
ClASsification for Psoriatic ARthritis (CASPAR) criteria were subsequently developed in 
2006 26. The overlapping clinical, immunological and genetic characteristics of the 
‘seronegative arthritides’ led to the suggestion that these conditions could be considered a 
single entity called SpA, including axial spondyloarthritis (axSpA) (extending the former 
definition of AS to include those identified by nonradiographic means), PsA, enteropathic 
arthritis, reactive arthritis and undifferentiated SpA, with a combined population prevalence 
of 1-2% 27,28. These conditions all have differing components of peripheral and axial (spine 
and sacro-iliac joint) arthritis, enthesitis, dactylitis, uveitis, inflammatory bowel disease 
(IBD), and psoriasis or psoriaform skin involvement 29. The non-articular disease 
components, such as psoriasis or Crohn’s disease, can be the dominant manifestation of these 
diseases. The broadening of the definition of SpA reflects increasing awareness of non-
rheumatoid inflammatory arthritis as well as the impact of new imaging modalities.  
 
Role of IL-17 family members in SpA  
Although the mechanisms underlying SpA pathogenesis have not been completely elucidated, 
evidence suggests a clear role for the IL-23/IL-17 axis in this process. In the following 
section, we discuss the association of genetic variants in the major histocompatibility 
complex (MHC) class I pathway and the IL-23/IL-17 axis with susceptibility to SpA. We 
briefly review the role of IL-23/IL-17 in animal models of inflammatory arthritis, and discuss 
data regarding the presence of IL-17 family members in the blood and tissues of patients with 
SpA. Finally, we discuss how IL-17 could promote joint inflammation and disrupt bone 
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homeostasis by synergising with other proinflammatory cytokines. 
 
Genetics of SpA with a focus on the MHC class I pathway and the IL-23/IL-17 axis 
Although some evidence suggests the involvement of MHC class II in AS 30, the strongest 
association with genetic susceptibility to SpA lies within the MHC class I region. To date, the 
HLA-B27 region represents the strongest genetic risk association identified in axSpA, PsA 
and reactive arthritis 31-33, and positivity for HLA-B27 is strongly associated with sacroiliitis 
in both AS and PsA. In addition, multiple other variants within the MHC class I loci are 
associated with PsA (including HLA-B39, HLA-Cw6, HLA-B38 and HLA-B08) or AS (HLA-
A02, HLA-B07), with some associations most evident when patients are stratified by clinical 
characteristics 30,34-36. The association of SpA with a variety of different HLA-B loci indicates 
that several immunological mechanisms could be altered by these genetic associations, 
including T cell repertoire selection and antigen presentation 37. Given that MHC class I 
molecules present peptides to CD8+ T cells, this genetic association suggests that CD8+ T 
cells are implicated in SpA. Initially, variants in the HLA-B27 region were thought to 
contribute to disease susceptibility through direct presentation of an arthritogenic peptide to 
cytotoxic CD8+ T cells 38. Alternative data suggest that variants within this locus promote 
HLA-B27 homodimerization, instead of heterodimerization with 2 microglobulin 39 or that 
HLA-B27 protein misfolding occurs, activating the unfolded protein response and increasing 
IL-23 production 40,41. Finally, HLA-B27 homodimers bind with increased affinity to killer 
cell immunoglobulin-like receptor 3DL2 (KIR3DL2), which is expressed on IL-17+ CD4+ T 
cells from the blood and synovial fluid of patients with AS 42. These data suggest a link 
between MHC class I and the IL-23/IL-17 axis.  
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In addition to the HLA region, variants in the ERAP1/2 loci (which encode enzymes required 
for HLA class I peptide trimming 43-45), and the RUNX3 locus, which encodes runt-related 
transcription factor 3, a transcription factor essential for CD8+ T cell development and 
differentiation 46-48, are associated with AS and PsA as well as psoriasis 49-52. The location of 
susceptibility variants associated with PsA has been shown to overlap with epigenetic marks 
of transcription (histone H3 lysine 4 trimethylation (H3K4me3), a histone modification and 
epigenetic marker of active promoters) in memory CD8+ T cells 52; in AS, susceptibility 
variants overlap with H3K4me3 marks across a range of immune cell types, including CD4+ 
and CD8+ T cells 53. Furthermore, risk and protective variants in the RUNX3 region correlate 
with variations in CD8+ T cell counts 49,54 and transcription factor (interferon regulatory 
factor 4, IRF4) binding 55, respectively. These genetic data provide a strong rationale to 
suggest the involvement of CD8+ T cells in SpA.  
 
An additional pathway highlighted by genetic association studies in SpA is the IL-23/IL-17 
axis. Variants in the IL12B region, which encodes the IL-12p40 subunit shared between IL-
12 and IL-23, are associated with AS and PsA, as well as with psoriasis and IBD 49,50,56,57; a 
variant in the IL23A region that encodes the IL-23p19 subunit is also associated with PsA and 
psoriasis 58. Furthermore, susceptibility variants in the IL23R locus (which encodes IL-23 
receptor) are associated with AS, PsA, psoriasis and IBD 45,49,56,57,59. In patients with AS, 
susceptibility variants in the IL23R locus are associated with altered transcript levels of genes 
related to the T helper 1 (TH1) and/or TH17 cell response including IL17A and RORC 60. 
These data suggest the involvement of IL-23 in the development of SpA. Interestingly, SpA 
and Behçet syndrome have several overlapping genetic associations (for example, variants in 
IL23R, ERAP1 and HLA class I genes), indicating that these ‘MHC-I-opathies’ may have 
similar underlying immunopathology 61. 
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As IL-23 is known to be important for sustained IL-17 production, it is interesting that 
additional susceptibility variants associated with inflammatory diseases have been identified 
in genes encoding IL-23/IL-17-related signalling molecules including TYK2, TRAF3IP2 and 
STAT3. Variants in the TYK2 locus, encoding a tyrosine kinase required for IL-23 signalling, 
are associated with AS, PsA and IBD 52,56,59. Variants in the TRAF3IP2 (which encodes 
NFB-activator 1 (ACT1; also known as TRAF3IP2) are associated with PsA, psoriasis and 
IBD 50,52,59. ACT1 is a key ubiquitin ligase required for IL-17 signalling through the IL-17 
receptor complex and subsequent induction of the NFκB pathway 62 (Box 3). Furthermore, 
genotyping studies have shown a suggestive association between STAT3 and AS 63,64 and PsA 
65. Signal transducer and activator of transcription 3 (STAT3) is a transcription factor induced 
upon IL-23 (as well as IL-6 and IL-21) signalling in CD4+ T cells and is a main regulator of 
the differentiation and function of IL-17 producing CD4+ T cells 66,67.  
 
Finally, studies have reported genetic associations with TNFAIP3 (which encodes TNF-
induced protein 3) and/or TNIP1 (which encodes TNFAIP3-interacting protein 1) in psoriasis 
68, PsA 52 and IBD 59, with a suggestive association for AS 69. TNFAIP3 is an anti-
inflammatory, ubiquitin modifying enzyme that can dampen NFkB-mediated inflammation 
and that has been implicated in multiple autoimmune and inflammatory conditions; TNFAIP3 
restrains IL-17 signalling in stromal cells 70. TNIP1 is a critical factor controlling IL-17 
biology in non-hematopoietic cells (keratinocytes and fibroblasts) both in vivo and in vitro 71. 
Figure 2 is a hypothetical depiction of how susceptibility genes associated with SpA might 
influence both CD8+ and CD4+ T-cell-related IL-23/IL-17-mediated immune responses.  
 
IL-17 in animal models of SpA  
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A key role of IL-17 and IL-23 dependent pathways has been shown in many inflammatory 
arthritis models, including the early models said to represent RA, and those developed to 
model aspects of SpA. The adjuvant arthritis model, which uses arthritis-prone rat strains and 
the potent adjuvant Complete Freund’s Adjuvant, is T-cell-dependent, lacks autoantibodies, 
and produces a resolving destructive inflammatory peripheral arthritis, osteitis and ankylosis 
of the tail 72. The first demonstration that inhibiting IL-17A in an animal model reduced 
disease activity and joint damage was reported in this model 73. Furthermore, collagen-
induced arthritis (CIA), the archetypal model for RA, cannot be induced in IL-17 or IL-17R 
knockout animals 74-76; development of arthritis in this model is dependent on IL-17 in the 
early phases, and partly suppressed by IL-17A inhibition during the active inflammatory 
phase. Conversely, overexpression of IL-17 with adenoviral vectors exacerbates CIA severity 
and joint destruction 77. In the streptococcal cell wall model of inflammatory arthritis, 
prevention of IL-17 signalling blocks transition from transient arthritis to persistent arthritis 
after repeated inoculations 78.  
A comprehensive review of animal models of pathogenic SpA pathways classified the models 
into related groups of HLA-B27 overexpression, TNF overexpression, IL-23 dependent 
models and curdlan-induced arthritis in SKG mice 79. Studies of mechanisms of B27 
overexpression in rats demonstrated expansion of IL-17+ CD4+ T cells 40,80, whereas a role 
for CD8+ T cells was not supported 81,82. The SKG mouse, which has a tyrosine-protein 
kinase Zap70 T cell receptor defect, develops arthritis and autoantibodies in response to a 
natural fungal lung infection; this model was originally described as a model for RA 83. 
However, specific pathogen-free mice injected with fungal derivatives develop different 
features, with downstream effects on SpA-associated genes. A detailed study of this model 
revealed many SpA features, including gut and skin inflammation and uveitis, followed by 
autoantibody formation 84. IL-23 mediates the effects on local mucosal dysregulation and the 
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production of cytokines driving the SpA syndrome, including IL-17-dependent arthritis and 
IL-22-dependent enthesitis 85.  
Enthesitis precedes joint inflammation in the CIA model 86, and the introduction of 
exogenous IL-23 by mini-circle DNA implants results in enhanced enthesitis. This process is 
mediated by IL-17 produced by IL-23R+ CD3+ CD4- CD8- lymphoid cells resident at the 
enthesis 87. Finally, certain mouse strains spontaneously develop a dermatitis resembling 
psoriasis and joint ankylosis as they age, and important roles of IL-17 have been described in 
these models particularly in the early stages of the disease 88,89.  
 
Presence of IL-17A and IL-17F cytokines in SpA  
Several studies have reported increased IL-17 production or enhanced IL17 mRNA 
expression in the serum, synovial fluid or tissue of patients with RA compared to patients 
with osteoarthritis (OA) and healthy individuals, indicating the presence of IL-17 in immune-
mediated arthritis 13,15,90-94. IL-17 has also been detected in the serum or synovial fluid of 
patients with early RA, suggesting its importance in disease initiation 94,95.  
 
Compared with RA, fewer studies have focused on SpA; however, IL-17 and/or IL-23 levels 
are substantially higher in serum from patients with SpA (consisting of AS, reactive arthritis 
and/or undifferentiated SpA) than in age and sex-controlled healthy individuals 96,97. In 
patients with AS, serum levels of IL-17 positively correlated with disease activity, as 
measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 98,99. 
Regarding the site of inflammation, higher levels of IL-17 have been detected in the synovial 
fluid than in the serum of patients with PsA 91, and in the synovial fluid of patients with 
reactive arthritis or undifferentiated SpA than in the synovial fluid of patients with OA or 
RA100. Furthermore, flow cytometry and western blot analysis revealed higher IL-17 receptor 
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A (IL-17RA) expression in synoviocytes from patients with PsA (and RA) than in OA 
synoviocytes 101. An intestinal biopsy study described upregulation of IL23A (which encodes 
the p19 subunit) transcripts in the terminal ileum of patients with AS, suggesting that the gut 
is an important source of IL-23 in AS; however, upregulation of IL17 mRNA was not 
observed in the same samples 102.  
Data in the literature both support 103,104 and refute 105 the presence of IL-17F in RA, with few 
data available regarding the presence of IL-17F in SpA. Increased IL-17F expression, as 
measured by immunohistochemistry staining, was observed in synovial tissue from patients 
with PsA compared to OA synovial tissue 106, and IL17F mRNA expression was noted in 6 
out of 14 synovial tissue samples from patients with PsA 107.  
Synergistic effects of IL-17A and IL-17F 
IL-17A can exert potent synergistic effects in the presence of other cytokines and mediators 
to augment proinflammatory responses, which could contribute to rheumatic disease. 
Although few studies have investigated the synergistic effects of IL-17A in the context of 
SpA, the literature on RA and experimental in vitro and in vivo systems is extensive, 
providing valuable insight into the synergistic function of IL-17A and its potential role in 
SpA (Figure 3).  
 
One of the best-studied synergies is IL-17A with TNF. Reports show that IL-17A can 
synergise with TNF to induce increased production of proinflammatory mediators such as IL-
6, IL-8 and CCL20 from RA synoviocytes 103,108,109. The synergy between IL-17A and TNF 
enhances granulopoiesis by inducing increased levels of GM-CSF in RA synoviocytes 108 and 
G-CSF from human epithelial cells 110. Moreover, IL-17A can combine with TNF to exhibit 
synergistic effects on the induction of CCL2 and CXCL2 from mouse mesangial cells 111. In a 
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CIA mouse model, IL-17A and TNF overexpression in synovial tissue from knee joints 
results in increased joint inflammation and cartilage erosion; this process is associated with a 
synergistic increase in expression of S100A8 (an alarmin associated with cartilage 
destruction), IL-1β and MMPs112. Similarly, IL-17A and TNF synergistically increase levels 
of S100A8 in the antigen-induced arthritis mouse model 113 and increase MMP-2 and CXCR4 
expression by RA synoviocytes, leading to an increase in cell invasion as examined by 
transwell Matrigel invasion chambers 114.  
 
As previously mentioned, IL-17 can contribute to bone destruction by inducing production of 
RANKL and the induction of osteoclastogenesis. This destructive effect can be exacerbated 
in the presence of TNF. In the synovial membrane, mRNA levels of both IL17A and TNF are 
predictive of rapid joint damage progression in RA, particularly with shorter disease duration 
115. In an RA ex vivo bone explant model, the inhibitory effect of TNF blockade on collagen 
degradation was increased when combined with IL-17 and IL-1 blockade 116. In addition, a 
study of TNF transgenic mice demonstrated that dual IL-17 and TNF blockade was more 
effective at restoring bone homeostasis than blockade of IL-17 or TNF alone; combined IL-
17 and TNF inhibition led to decreased osteoclast and increased osteoblast numbers, 
increased osteocalcin levels and a reduction in RANKL levels, all contributing to protection 
from bone resorption 117. 
 
Whereas systemic bone loss can occur in both RA and SpA, a characteristic feature of SpA is 
ectopic bone formation. The exact roles of inflammatory cytokines in new bone formation are 
still incompletely understood (reviewed elsewhere 118). IL-17 can enhance the effects of TNF 
on bone matrix formation by mesenchymal stem cells (MSCs) 119. These cytokines can 
synergistically enhance the mineralization of the MSC extracellular matrix, which is a marker 
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of human MSC differentiation into osteoblasts. Alkaline phosphatase (ALP), an enzyme 
produced by MSCs that is essential for bone mineralisation, is increased in the presence of 
IL-17 and TNF, whereas MSC RANKL expression is substantially downregulated 119. 
However, further studies are required to determine the paradoxical effects of IL-17A and 
TNF on bone destruction and formation (Figure 3).  
 
In addition to TNF, IL-17A has been shown to synergise with other proinflammatory 
cytokines including IL-1β and IFNγ. The combination of IL-17A and IL-1β increases IL-6 
production by RA synoviocytes 120 and increases CCL20 production by fibroblast-like 
synoviocytes121. In the CIA mouse model, blocking both IL-17A and IL-1β reduces cartilage 
degradation and bone destruction and downregulates the expression of IL-1β, IL-6, IFNγ, 
RANKL and MMP-3 in cartilage tissue 122. Moreover, a bispecific antibody for IL-17A and 
IL-1β improves clinical signs of CIA mice compared to blocking IL-17A or IL-1 alone 123. 
IL-17A and IFNγ synergistically upregulate IL-6 and IL-8 production by keratinocytes and 
lead to a subtle increase in expression of intercellular adhesion molecule 1 (ICAM-1), a 
ligand that binds leukocyte adhesion glycoprotein LFA-1 -chain (LFA-1A; also known as 
ITGAL) on T cells to cause T cell adhesion to keratinocytes 124. This mechanism could 
augment inflammation in diseases of the skin, such as psoriasis. 
 
Similar to IL-17A, IL-17F can synergise with other cytokines, amplifying its inflammatory 
potential. Real-time RT-PCR analysis revealed that IL-17F synergises with TNF to augment 
IL6, IL8 and CXCL5 mRNA levels from RA synoviocytes. Although the combination of IL-
17A and TNF induces a higher fold increase in levels of mRNA for proinflammatory 
cytokines than IL-17F and TNF, the effect of IL-17F and TNF synergy is potent 103. IL-17F 
can also synergise with TNF to induce elevated levels of G-CSF from human epithelial cells 
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110 and synergises with both TNF and IL-1, enhancing the expression of CCL2 and CXCL2 
from mouse mesangial cells 111.  
 
Although studies have demonstrated the proinflammatory capability of IL-17F, it remains to 
be firmly established that IL-17F contributes to the immunopathology of SpA; robust 
evidence confirming the presence and function of IL-17F in SpA is still lacking. However, if 
IL-17F is present, it has the potential to contribute to SpA pathology;  reports suggest that IL-
17F is not redundant to IL-17A and that dual blockade of these cytokines can further reduce 
inflammation compared with blockade of IL-17A alone. In a mouse model of colitis, 
combined blockade of IL-17A and IL-17F was more effective at ameliorating disease than 
blockade of IL-17A alone 125. Moreover, dual neutralization of IL-17A and IL-17F might 
have a more profound effect on reducing TH17 cell culture supernatant-induced IL-8 and IL-6 
production by synoviocytes from patients with PsA and healthy human dermal fibroblasts 
than inhibition of IL-17A or IL-17F alone 107.  
 
The mechanisms underlying the synergy of IL-17A and IL-17F with other cytokines remain 
to be fully elucidated; however, the synergistic effect might occur through the ability of IL-
17A to stabilise mRNA transcripts. The IL-17A and TNF synergistic increase in IL-8 protein 
and gene expression has been shown to be the result of IL-17A extending the half-life of the 
unstable TNF-induced IL8 mRNA (Figure 3) 126. Given that cells pre-treated with a p38 
mitogen-activated protein kinase (MAPK) inhibitor displayed an increased IL8 mRNA decay 
rate after stimulation with IL-17A and TNF, IL-17A-induced mRNA stabilisation is proposed 
to be a p38 MAPK-dependent pathway 126. The importance of ACT1 in IL-17A-induced 
stabilisation has also been highlighted 8, and other mRNA transcripts including MIP2 and 
CSF2 (which encodes GM-CSF) whose half-lives were extended in response to IL-17A have 
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been identified, implicating this as a common mechanism for IL-17A synergy. To date, no 
studies have investigated the ability of IL-17F to stabilise mRNA transcripts. The synergistic 
effect of IL-17A and TNF might also be mediated by phospholipase D enzymes, which 
upregulate cytokine secretion 127; inhibition of these enzymes in vitro in RA fibroblasts that 
are cultured with IL-17A and TNF leads to decreased production of IL-6, IL-8 and CCL20 
127. 
IL-17 producing T cells in SpA 
Several cell types have been shown to produce IL-17, including T cells, innate lymphoid 
cells, NK cells, neutrophils and macrophages 4,128-130. Here we focus on key T cell subsets 
that have been identified as sources of IL-17 in SpA. 
 
IL-17A+ CD4+ T (TH17) cells in SpA  
The presence of CD4+ T cells expressing IL-17 (TH17 cells, Box 2) in the inflamed 
rheumatoid joint has been documented extensively in patients with RA and juvenile 
idiopathic arthritis (JIA) 15,90,91,131-134, with evidence of correlations between the frequencies 
of these cells and disease activity or clinical phenotype 15,91,132. In SpA, IL-17+ CD4+ T cells 
are present in higher frequencies in the peripheral blood of patients with PsA and AS than in 
healthy controls 135,136. Furthermore, several studies have demonstrated the presence of IL-
17+ CD4+ T cells in the synovial fluid of patients with PsA, AS or reactive arthritis 
91,134,137,138. As well as identifying increased IL-17+ CD4+ T cell frequencies in the peripheral 
blood of patients with psoriasis or PsA compared to healthy controls, increased frequencies of 
IL-17+ CD4+ T cells have also been identified in psoriatic lesional skin compared with skin 
from healthy individuals 139. In patients with AS, frequencies of peripheral blood IL-17+ 
CD4+ T cells positively correlate with disease activity 99. Correlations between IL-17+ CD4+ 
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T cells percentages from the synovial fluid and levels of C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR), fibrinogen, synovial fluid neutrophil count and 
synovial fluid total leukocyte count was also reported in a cohort of patients diagnosed with 
RA, SpA, undifferentiated SpA, reactive arthritis, microcrystal arthritis, gout and pseudogout 
140.  
 
IL-17+ CD8+ T cells in SpA  
Evidence is increasing that CD8+ T cells are another cellular source of IL-17 (reviewed 
elsewhere 128). An initial study reported IL17 mRNA expression by human CD8+ T cell 
clones isolated from skin lesions of patients with psoriasis 124 (Figure 1). To date, the 
presence of IL-17+ CD8+ T cells has been shown in multiple immune-mediated 
inflammatory diseases such as psoriasis, multiple sclerosis and PsA134,141-144. An elegant 
study showed that IL-17+ CD8+ T cells are enriched in the epidermis of human psoriatic skin 
lesions, and that neutralizing anti-CD8 monoclonal antibody treatment of mice 
xenotransplanted with human psoriatic skin resulted in complete blockade of psoriasis 
development 145.  
 
In SpA, IL-17+ CD8+ T cells are present in the peripheral blood of patients with AS, with the 
highest frequencies of these cells observed in patients with severe disease 146. Furthermore, 
within the inflammatory joint, increased frequencies of IL-17+ CD8+ T cells are detected in 
the synovial fluid of patients with PsA or AS compared with peripheral blood from the same 
patients 134,138. In PsA, this enrichment correlated with markers of disease activity such as the 
results of power Doppler ultrasonography and CRP levels 134. Extensive immunophenotyping 
of IL-17+ CD8+ T cells from the synovial fluid of patients with SpA indicates that these cells 
have proinflammatory potential 147. Notably, although frequencies of IL-17+ CD8+ T cells 
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are increased in the inflamed joints of patients with SpA, this enrichment has not been 
observed in the synovial fluid from patients with RA134. Thus, IL-17+ CD8+ T cells might 
specifically contribute to the pathogenesis of HLA class I-associated SpA, but not to HLA 
class II-associated RA.  
 
TRM cells in SpA  
Tissue resident memory (TRM) T cells are a subset of CD8+ or CD4+ T cells that do not re-
circulate through the peripheral blood and lymphoid tissues 148,149. Originally described in 
mice 150, TRM cells are found in barrier tissues such as the lung, gut, skin, liver and genital 
tract 148,151,152, and have the potential to express IL-17A152,153. Characterised by expression of 
markers CD69 and/or CD103 (also known as ITGAE), TRM cells are retained within tissue 
after activation, inducing a local inflammatory response through production of cytokines and 
cytotoxic mediators (reviewed elsewhere 154). The transcription factor RUNX3 has been 
described as a key regulator of TRM cell differentiation and homeostasis in mice 155. 
Presently, very few human studies have described TRM cells in patients with immune-
mediated inflammatory diseases, although CD8+ TRM cells have been described in both 
healthy and psoriatic skin, where TRM cells express several cytokines including IFNy, IL-17A 
and IL-22 144,152,156,157. Less is known about CD4+ TRM cells but they have been described in 
human skin 151. Furthermore, IL-17A expressing TRM cells were described as disease drivers 
in an experimental SpA mouse model 87. In the context of inflammatory arthritis, few data 
have been published as yet, but these cells might be present in the synovial fluid of patients 
with JIA158 and SpA 147. Thus, this cell type might emerge as a relevant inflammatory cell 
type in the pathogenesis of inflammatory arthritis.  
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Mucosal-associated invariant T cells 
MAIT cells are innate cells characterised by their variable region- (Vα)7.2-joining region-
(Jα)33 rearrangement 159, high CD161 (also known as KLRB1) expression and MHC class 
I-related gene protein (MR1) restriction 160,161. After stimulation with PMA (phorbol 
myristate acetate) and ionomycin, some MAIT cells produce IL-17, IFNγ, TNF or the 
cytolytic molecule granzyme B 162. IL-17-producing CD8+ MAIT cells have been identified 
in psoriatic skin and blood from patients with psoriasis 163; notably, frequencies of 
conventional Vα7.2- IL-17+ CD8+ T cells were higher than Vα7.2+ IL-17+ CD8+ (MAIT) T 
cells in the psoriatic skin.162 We have previously identified low frequencies of IL-17-
producing CD8+ CD161+ Vα7.2+ MAIT cells within the IL-17+ CD8+ T cell population in 
the synovial fluid of patients with PsA 134. IL-17+ MAIT cells have also been identified at 
higher frequencies within the peripheral blood of patients with AS compared to the peripheral 
blood of healthy controls 164,165.  
 
Invariant Natural Killer T cells 
To date little evidence exists for the presence of IL-17-producing invariant NKT cells in SpA. 
One mouse study reported lower incidence and disease severity of induced arthritis in NKT-
cell-deficient Jα281-/- mice than in B6 mice 166. NKT cells were found to produce IL-17; 
Jα281-/- splenocytes produced little IL-17 compared to B6 splenocytes. In addition, a lower 
proportion of TH17 cells was observed in Jα281-/- mice than in B6 mice, suggesting that NKT 
cells maintain or activate TH17 cells, which can contribute to inflammatory disease.  
 
γδ T cells 
 T cells are a subset of T cells that combine typical features of adaptive T cells (antigen 
recognition via T cell receptors and pleiotropic effector functions) with an ability to 
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respond in a rapid, innate-like manner. These cells are present in the blood but 
predominantly reside in specific tissues. IL-17 expressing γδ T cells were initially described 
in patients with psoriasis, in whom the reduced percentage of variable domain- (Vγ)9Vδ2 T 
cells in the peripheral blood was attributed to an increase in cell trafficking to the inflamed 
skin 167. Subsequently, the frequency of IL-17A expressing γδ T cells was reported to be 
increased in the peripheral blood of patients with PsA, AS, reactive arthritis and enthesis-
related JIA compared with healthy controls 168-170. IL-17A+ γδ T cells are also enriched in the 
synovial fluid compared with the peripheral blood of patients with PsA, reactive arthritis or 
undifferentiated SpA 170,171.  
 
In mice, IL-23 responsive dermal γδ T cells secrete IL-17A, IL-17F and IL-22 and are 
implicated as key producers of IL-17A during psoriatic skin inflammation 172-174. In a mouse 
model of SpA, retinoid-related orphan receptor- (RORC)+ IL-17A expressing γδ T cells 
accumulate in the enthesis, aortic root and eye, which are tissue sites commonly affected by 
SpA 175.  
 
Other cellular sources of IL-17 in SpA 
In addition to T cells, other non-T cell subsets have been identified as sources of IL-17. 
Increased levels of IL-17-producing group 3 innate-lymphoid cells (ILC3), a lineage negative 
cell population, have been identified in the peripheral blood of patients with PsA compared 
with healthy controls, the levels of which correlate with disease activity 176. Increased levels 
of these cells have also been detected in the synovial fluid of patients with PsA compared 
with those with RA 177. 
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Other IL-17-producing cell types include CD3- CD56+ NK cells, which are found at higher 
levels in the peripheral blood of patients with enthesitis-related arthritis than in healthy 
controls 169. Increased levels of IL-17-producing NK cells have also been identified in the 
synovial fluid in comparison to peripheral blood of patients with reactive arthritis or 
undifferentiated SpA 171. Immunofluorescence microscopy on synovial tissue from patients 
with SpA showed co-localisation of tryptase-positive cells, identified as mast cells, and IL-
17+ cells, suggesting the presence of IL-17-producing mast cells in SpA 178. However, further 
studies demonstrated that mast cells do not synthesize IL-17, but rather capture, store and 
release bioactive exogenous IL-17A 179. 
 
IL-23/IL-17 targeted therapies in SpA 
Targeted therapies using cytokine specific monoclonal antibodies provide some of the most 
compelling evidence for the important roles of specific cytokine pathways in disease 
pathogenesis 180. Studies investigating IL-23/IL-17-directed therapies have helped define the 
complexities of these pathways in SpA and related conditions such as psoriasis and IBD 181. 
Ustekinumab, which targets the p40 subunit shared by both IL-12 and IL-23, was the first 
agent to show superior efficacy over TNF inhibitors in patients with psoriasis182-184, albeit 
with less efficacy than TNF inhibitors in PsA 185,186. High doses of this drug are also effective 
in Crohn’s disease 187.  
 
Anti-IL-17A directed therapies, initially secukinumab and then ixekizumab, have yielded 
outstanding responses in psoriasis, which have changed expectations of therapy; PASI90 (an 
improvement of 90% or more with respect to baseline Psoriasis Area and Severity Index 
score) and almost clear or clear responses occur in many patients, showing superiority to 
etanercept, adalimumab and ustekinumab 188-193. Both secukinumab and ixekizumab have 
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shown efficacy in PsA. Secukinumab is also licensed for AS, with arthritis responses similar 
to those for TNF inhibitor therapy 194-199 but with no effect in uveitis 200. In contrast to 
ustekinumab, IL-17 inhibition with secukinumab or ixekizumab is associated with low levels 
of exacerbation of IBD, demonstrating that IL-17A has a complex role 201. Brodalumab, 
which is directed at IL-17RA and thereby blocks IL-17A, IL-17C, IL-17E and IL-17F 
signalling, has shown good efficacy in psoriasis and PsA 202-204, but causes exacerbation of 
Crohn’s disease 205. Bimekizumab, a bifunctional antibody that blocks both IL-17A and IL-
17F, has demonstrated good efficacy in a proof-of-concept study in 39 patients with PsA 107, 
although randomised head-to-head studies are required to clarify whether dual IL-17A and 
IL-17F blockade is superior to IL-17A alone (as discussed above).  
Specific inhibition of IL-23 by monoclonal antibodies targeting the IL-23p19 component has 
shown excellent efficacy in psoriasis, with response levels at least the same as for IL-17A 
inhibitors. Guselkumab, now licensed for psoriasis 206,207, has also shown efficacy in a phase 
II study of PsA 208,209; tildrakizumab has demonstrated efficacy in a phase III study of 
psoriasis, and risankisumab has shown efficacy in phase II studies in psoriasis and Crohn’s 
disease 210-212.  
These clinical data help our understanding of the complex biological effects of IL-23/IL-17 
pathways in SpA and related conditions. Data from skin and synovial tissue samples from 
patients with psoriasis and PsA, showing more extensive IL-17-related activation networks in 
skin versus synovial sites 213, might explain the difference in outcome of IL-17A inhibition in 
psoriasis versus PsA. Likewise, the differential responses of IL-23 versus IL-17A inhibition 
in Crohn’s disease shows the complex role of IL-17A in the gut; furthermore, other effects of 
IL-23, such as IL-22 induction, might have an additive role.  
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Conclusions 
The clinical, genetic and experimental evidence for a pathogenic role of IL-17A in SpA is 
compelling. In particular, the profound clinical efficacy of several drugs that target the IL-
23/IL-17 pathway unequivocally demonstrates the contribution of this pathway in SpA. 
Importantly, IL-17A is not a sole contributor to SpA pathogenesis but acts in synergy with 
several other cytokines to drive the production of numerous other proinflammatory and 
tissue-modifying mediators. As is the case in other complex immune-mediated inflammatory 
diseases, SpA is probably the result of a combination of different factors culminating in 
imbalanced immune reactivity. The genetic evidence in SpA indicates the involvement of 
certain gene variants that might affect peptide presentation (MHC class I genes and 
ERAP1/2), alter CD8+ T cell development or differentiation (RUNX3), and/or promote 
increased IL-23 and/or IL-17 production (IL23, IL23R, STAT3) or IL-23/IL-17 signalling 
(TYK2 and TRAF3IP2). Notably, targeted therapy using anti-cytokine monoclonal antibodies 
generally means that the targeted cytokine is inhibited regardless of the cellular source(s). 
The genetic and experimental evidence presented in this Review indicates that IL-17+ CD8+ 
T cells might be an important contributing source of IL-17A in SpA; however, these cells are 
not the only source of IL-17A. Whether IL-17 production by different cellular sources results 
in differential immunopathological effects remains to be established; these different effects 
could include, for example, differential cytokine co-expression leading to synergistic versus 
antagonistic effects, differences in migratory versus tissue-resident capacity by the IL-17 
producing cell, co-existing cytotoxic potential, or as yet unknown factors. A detailed 
understanding of the cellular source(s) and molecular regulation of IL-17 in SpA might open 
up novel avenues to specifically intervene in the production of this cytokine, and thus help to 
ameliorate disease. 
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Key points  
• Genetic and animal model studies indicate that the IL-23/IL-17 axis is involved in the 
pathogenesis of spondyloarthritis (SpA). 
• IL-17A has been identified directly in the blood and synovial fluid of patients with 
SpA, with T cells representing a key source of this cytokine.  
• IL-17A and IL-17F act in synergy with other proinflammatory mediators to induce 
proinflammatory responses across a range of cell types. 
• IL-23/IL-17 targeted therapies have been shown to be effective in psoriatic arthritis 
and ankylosing spondylitis. 
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• Increased understanding of the pathogenic role of the IL-23/IL-17 axis, their cellular 
sources and molecular regulation in SpA is essential to develop novel therapeutic 
strategies targeting this pathway. 
 
 
BOX 1. The IL-17 cytokine family 
• IL-17A was first identified in 1993 through a subtractive hybridization screen of a 
rodent T cell library (then referred to as cytotoxic T lymphocyte antigen 8, CTLA8) 1 
(Figure 1). Subsequent work detected IL17A mRNA in a human CD4+ T cell clone 
5,214.  
• Proteomic and genomic database searches led to the discovery of the remaining IL-17 
family members, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F, all of which display a 
degree of similarity in amino acid sequences to IL-17A 215-217.  
• Using nested RACE (rapid amplification of cDNA ends) PCR, IL-17F was first 
cloned, bearing the strongest (50%) homology to IL-17A. The IL17F gene was found 
to be located adjacent to IL17A on chromosome 6p12, and expression of IL-17F was 
observed in activated CD4+ T cells 217.  
• Both IL-17A and IL-17F can be secreted as homodimers. In addition, mouse and 
human studies have identified an IL-17AF heterodimer 16,218. 
 
BOX 2 TH17 lineage discovery 
• In 2005, two landmark studies defined IL-17A and IL-17F producing CD4+ T cells 
(TH17 cells) as a distinct CD4+ T cell lineage separate from TH1 and TH2 cells 219,220 
(Figure 1).  
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• TH17 differentiation is dependent on signals from IL-6, transforming growth factor β 
(TGFβ), IL-1β and IL-21, whereas IL-23 is important for lineage maintenance 221-226. 
IL-23 has also been shown to contribute to the pathogenicity of TH17 subsets 219,227.  
• The main regulator of TH17 cells is the transcription factor retinoic acid related 
orphan nuclear receptor γ (RORγt) 228. Other transcription factors that contribute to 
TH17 differentiation include RORα, signal transducer and activator of transcription 3 
(STAT3), interferon regulatory factor 4 (IRF4) and aryl hydrocarbon receptor (AHR) 
66,229-232.  
• In addition to IL-17A and IL-17F, TH17 cells can produce an array of other cytokines 
including IFN, TNF, GM-CSF (granulocyte-macrophage colony-stimulating factor), 
IL-21, IL-22, IL-9 and IL-10. The presence and expression levels of these cytokines 
depend on the cytokine milieu present upon TH17 polarisation 233-237, and they may 
synergise with or antagonise IL-17 function 233,235,236,238.  
  
BOX 3 IL-17 Receptors and IL-17 Signalling 
• The biological functions of IL-17 cytokines are mediated via surface receptors on 
target cells. There are five members of the IL-17 receptor family, IL-17 receptor A 
(IL-17RA), IL-17RB, IL-17RC, IL-17RD and IL-17RE.  
• Functional IL-17 receptors exist as heterodimers, with IL-17RA as a common subunit. 
The IL-17RA and IL-17RC heterodimer is the receptor for IL-17A, IL-17F and IL-
17A-IL-17F 239.  
• IL-17RA is ubiquitously expressed at particularly high levels by hematopoietic cell 
types, whereas IL-17RC is preferentially expressed by non-hematopoietic cells 240.  
• As IL-17A and IL-17F require IL-17RA and IL-17RC to exert their effects, these 
cytokines typically act on fibroblasts, epithelial cells and endothelial cells 240.  
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• Although the binding affinities of IL-17A and IL-17F for IL-17RC are comparable, 
research has shown a higher affinity of IL-17A for IL-17RA than IL-17F 218,241. 
• A conserved region known as the similar expression of fibroblast growth factor genes 
and IL-17Rs (SEFIR) domain is located at the carboxy terminus of all IL-17 
receptors. Upon IL-17 stimulation, the cytosolic protein nuclear factor-B (NF-B) 
activator 1 (ACT1; which is encoded by TRAF3IP2) is recruited to the IL-17 complex 
through homotypic interactions of the SEFIR domain 242,243.  
• ACT1 serves as both a signalling adaptor, recruiting TNF receptor-associated factor 6 
(TRAF6) proteins, and an E3 ligase, mediating the ubiquitination of TRAF6. This 
process leads to the activation of the canonical nuclear factor-κB (NFκB) pathway and 
mitogen-activated protein kinase (MAPK) pathways 242,243.  
• A unique TRAF6-independent signalling pathway involves ACT1-dependent 
recruitment of TRAF2 and TRAF5, and this pathway mediates IL-17A-dependent 
mRNA stabilisation (reviewed elsewhere 242,243). 
 
 
LEGENDS 
Figure 1. Key discoveries in the biology of IL-17A and IL-17-producing T cells. A 
timeline showing some of the major discoveries regarding IL-17A biology, IL-17 producing 
T cells and IL-17 targeted therapies is shown. AS, ankylosing spondylitis; CTLA8, cytotoxic 
T lymphocyte associated antigen 8; HVS13, Herpesvirus samiri; IL-23R, interleukin-23 
receptor; PsA, psoriatic arthritis; RA, rheumatoid arthritis; TRM cells, tissue resident memory 
cells. 
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Figure 2. Hypothetical depiction of how spondyloarthritis susceptibility genes might 
influence IL-23/IL-17-mediated immune responses.  
RUNX3 variations might influence CD8+ T cell development or differentiation or the 
generation of tissue-resident memory (TRM) cells. Gene variants in ERAP1/2 might alter 
peptide trimming and thus major histocompatibility complex (MHC) class I-mediated peptide 
presentation to CD8+ T cells. MHC class I genotype can further influence peptide 
presentation to CD8+ T cells and/or lead to the formation of HLA-B27 homodimers. HLA-
B27 homodimers can bind to killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2), 
eading to IL-17 production by CD4+ T cells. Genetic variants in IL12B, IL23A, IL23R and 
TYK2 might lead to enhanced IL-23 production and/or signalling, resulting in increased or 
sustained IL-17 production by CD8+ and CD4+ T cells. This increased IL-17 production 
might be exacerbated by genetic variations in STAT3, which signals downstream of IL-6, IL-
21 and IL-23, all of which are important drivers of IL-17 production. Lastly, genetic variants 
in TRAF3IP2 could lead to altered IL-17 signalling, while variants in TNIP1 and/or TNFAIP3 
might influence nuclear factor-B (NFB) signalling. Together, these mechanisms could 
lead to enhanced IL-17 mediated biological effects (for example, production of IL-6, IL-8, 
CXCL1 and CCL20 in IL-17 receptor (IL-17R)-positive target cells. ER, endoplasmic 
reticulum; ERAP, ER aminopeptidase; IL-23R, IL-23 receptor; SpA, spondyloarthritis; TCR, 
T cell receptor. 
 
 
Figure 3. Potential synergistic activity of IL-17A and TNF in the spondyloarthritis joint. 
CD4+ and CD8+ T cells expressing IL-17A and TNF can act on target cells such as synovial 
fibroblasts in the inflamed spondyloarthritis joint. IL-17A can synergise with TNF, leading to 
increased production of proinflammatory mediators including IL-6, IL-8, CC-chemokine 
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ligand 20 (CCL20) and CXC-chemokine ligand 1 (CXCL1). Although the mechanisms of IL-
17A and TNF synergy are not yet fully understood, it has been reported that IL-17A can 
extend the half-life of the unstable TNF-induced IL8 mRNA via p38 mitogen-activated 
protein kinase (MAPK) and nuclear factor-B (NFB) activator 1 (ACT1)-dependent 
pathways. The subsequent elevated levels of IL-8, IL-6 and CCL20 recruit neutrophils and 
lymphocytes, leading to an enhanced inflammatory response. The combination of IL-17A and 
TNF has also been reported to exacerbate disruption of bone homeostasis. These cytokines 
can augment the upregulation of receptor activator of NFB ligand (RANKL) on osteoblasts 
and fibroblasts. Subsequently, osteoclast precursor cells expressing receptor activator of 
NFB (RANK) are differentiated into activated osteoclasts that mediate bone degradation. 
Conversely, IL-17A and TNF can augment ectopic bone formation by increasing 
mesenchymal stem cell (MSC) differentiation into osteoblasts via mineralization of the MSC 
extracellular matrix. This process is associated with increased alkaline phosphatase (ALP) 
levels and decreased RANKL expression. Differentiated osteoblasts can then deposit new 
bone tissue. However, further studies are required to determine the paradoxical effects of IL-
17A and TNF on bone destruction and formation. PsA, psoriatic arthritis; TH17, T helper 17. 
 
 
ToC 
Evidence from genetic, experimental and clinical studies has accumulated to indicate a role 
for the interleukin-17 (IL-17) pathway in the pathogenesis of spondyloarthritis. This Review 
discusses how IL-17A and IL-17F and their cellular sources contribute to the 
immunopathology of these diseases. 
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Figure 3. Taams et al.
Potential synergistic activity of IL‐17A and TNFα in the SpA joint 
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